Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s LY-3972406?
LY-3972406 is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris).
LY-3972406 is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris).
“You can’t take the pot off the fire [and] you can’t turn down the heat.” — Josh Pickett, RN, a charge nurse at Seattle Children’s
With syphilis cases in U.S. newborns skyrocketing, a doctors group now recommends that all pregnant patients be screened three times for the sexually transmitted infection.